Pfizer reaffirms 2026 guidance after CFO transition news
Tweet
Share
E-mail
Get Alerts PFE Hot Sheet
Price: $28.07 +1.01%
Financial Fact:
Restructuring charges and certain acquisition-related costs: 531M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Restructuring charges and certain acquisition-related costs: 531M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Pfizer (NYSE: PFE) reaffirmed its full-year 2026 financial guidance following the announcement of a Chief Financial Officer transition on June 18, 2026.
The company maintained its forecast for revenues in a range of $59.5 billion to $62.5 billion, and adjusted diluted earnings per share in a range of $2.80 to $3.00. The guidance was originally introduced on December 16, 2025, and was previously reaffirmed during Pfizer's first-quarter earnings call on May 5, 2026.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boeing names Ryan Shedd as new SVP and controller
- CoVolt Power files for proposed IPO
- Nuvectis Pharma (NVCT) files $200M mixed shelf
Create E-mail Alert Related Categories
Corporate News, Guidance, Management ChangesRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
